Kardigan

At Kardigan, a pioneering heart health company, we are fundamentally reshaping the landscape of cardiovascular drug development through groundbreaking innovation and a patient-centric approach. Our mission is to move beyond mere symptom management and deliver functional cures, transforming cardiovascular disease from a chronic illness into a preventable and curable condition. We are leveraging a sophisticated, proprietary cardiac intelligence platform that integrates real-world clinical data with advanced analytics. This allows for an unparalleled, deep understanding of disease mechanisms and individual patient responses to treatment. By meticulously matching critical disease drivers with the specific patients who will respond best to targeted therapies, we are streamlining the clinical trial process, enhancing efficacy, and dramatically accelerating the delivery of novel medicines to those in greatest need. Our integrated and efficient R&D platform utilizes a unique set of cardiac-specific tools to validate markers for safety and efficacy long before human studies commence, ensuring a higher probability of success for our late-stage clinical candidates.

This revolutionary approach is driven by a team of world-class cardiologists, cardiovascular scientists, and seasoned biotechnology executives who share a relentless passion for eliminating cardiovascular disease as the world's leading cause of death. The leadership, reunited after their monumental success at MyoKardia, brings a proven track record of innovation and operational excellence. By combining our cutting-edge discovery and translational research with strategic in-licensing and acquisitions, we are building a robust portfolio of personalized medicines. Kardigan is not just developing drugs; we are creating a new paradigm in cardiovascular medicine, one where therapies are precisely targeted to an individual's disease pathophysiology. This commitment to scientific rigor and technological advancement positions us at the forefront of the industry, poised to deliver a new generation of treatments that will bring patients closer to the cures they rightfully deserve and ultimately change the global trajectory of heart health.